Literature DB >> 19796464

Bilateral leiomyosarcoma of the kidney with family history of kidney cancer.

Huseyin Kadikoy1, Waqar M Haque, Veli K Topkara, Adam I Frome, Teresa G Hayes.   

Abstract

Sarcomas make up 1%-2% of all malignant renal tumors in adults, and the incidence increases with advancing age. Renal sarcomas are less common, but more lethal than sarcomas of any other genitourinary site. The common clinical presentation of renal sarcomas in adults include a palpable mass, abdominal or flank pain, and hematuria, similar to those seen with large, rapidly growing renal cell carcinomas. Usually, radical nephrectomy remains the treatment of choice for these tumors, which exhibit an aggressive biological behavior and an unfavorable prognosis. We describe an unusual case of bilateral renal leiomyosarcoma in a 61-year-old white male. The patient also had an uncle who had bilateral kidney cancer. In addition, our patient presented with a pulmonary embolism, which is different from the classic presentation of leiomyosarcoma. The patient did not undergo surgery, as the tumor had also invaded the surrounding vasculature and was felt to be unresectable by the consulting surgeons. He was treated with gemcitabine and docetaxel chemotherapy, with stabilization of disease.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19796464

Source DB:  PubMed          Journal:  Can J Urol        ISSN: 1195-9479            Impact factor:   1.344


  3 in total

1.  Bilateral leiomyosarcoma of kidneys with pericardial metastases: a double whammy.

Authors:  Santosh Kumar; Tushar Aditya Narain; Gopal Sharma; Shantanu Tyagi
Journal:  BMJ Case Rep       Date:  2019-03-20

2.  Concomitant leiomyosarcoma of the right kidney and squamous cell carcinoma of the cervix - an unusual clinical presentation.

Authors:  Tobe Momah; Vasantha Kondamudi; Sherly Abraham; Dhanan Etwaru; Ahulwalia Meena; Arnold Teo; Phillip Xiao
Journal:  Hematol Rep       Date:  2010-10-18

3.  Prognostic features of renal sarcomas (Review).

Authors:  Hakan Öztürk
Journal:  Oncol Lett       Date:  2014-12-30       Impact factor: 2.967

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.